Company intelligence / Profile preview

Shanghai Qiran Biotechnology

Shanghai, Shanghai, Chinaqiranbio.com ↗

Ownership: Private
Development stage: Other

Overview

Qiran Bio is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing innovative gene therapies using advanced AAV delivery systems. The company utilizes a proprietary platform for AAV capsid engineering and high-throughput screening to identify vectors with improved tissue tropism and reduced immunogenicity. Its lead program, QR001, is an AAV-based gene therapy targeting neovascular age-related macular degeneration (nAMD). Qiran Bio's broader pipeline addresses unmet needs in ophthalmology, metabolic disorders, and other rare diseases. The company is backed by prominent venture capital firms and maintains state-of-the-art R&D facilities in Shanghai.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV-based therapy
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Qiran Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Qiran Biotechnology.